CureVac NV Net Worth
CureVac NV Net Worth Breakdown | CVAC |
CureVac NV Net Worth Analysis
CureVac NV's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CureVac NV's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CureVac NV's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CureVac NV's net worth analysis. One common approach is to calculate CureVac NV's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CureVac NV's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CureVac NV's net worth. This approach calculates the present value of CureVac NV's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CureVac NV's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CureVac NV's net worth. This involves comparing CureVac NV's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CureVac NV's net worth relative to its peers.
Enterprise Value |
|
To determine if CureVac NV is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CureVac NV's net worth research are outlined below:
| CureVac NV had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 53.76 M. Net Loss for the year was (260.17 M) with loss before overhead, payroll, taxes, and interest of (86.28 M). | |
| CureVac NV currently holds about 540.87 M in cash with (267.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85. | |
| Roughly 45.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: CureVac N.V.s largest shareholders are individual investors with 38 percent ownership, private equity firms own 31 |
CureVac NV uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CureVac NV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CureVac NV's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 23rd of April 2024 Upcoming Quarterly Report | View | |
| 4th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 23rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know CureVac NV's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CureVac NV is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CureVac NV backward and forwards among themselves. CureVac NV's institutional investor refers to the entity that pools money to purchase CureVac NV's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 171.7 K | Deutsche Bank Ag | 2024-12-31 | 169.9 K | Freestone Capital Holdings, Llc | 2024-12-31 | 144.1 K | Legal & General Group Plc | 2024-12-31 | 114.8 K | Two Sigma Investments Llc | 2024-12-31 | 114.7 K | Susquehanna International Group, Llp | 2024-12-31 | 97.9 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 97.3 K | Pictet Asset Manangement Sa | 95.4 K | Dekabank Deutsche Girozentrale | 2024-12-31 | 85.6 K | Millennium Management Llc | 2024-12-31 | 1.6 M | Bill & Melinda Gates Foundation | 2024-09-30 | 1.6 M |
Follow CureVac NV's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 675.26 M.Market Cap |
|
Project CureVac NV's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.58) | (0.61) |
When accessing CureVac NV's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CureVac NV's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CureVac NV's profitability and make more informed investment decisions.
Please note, the presentation of CureVac NV's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CureVac NV's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CureVac NV's management manipulating its earnings.
Evaluate CureVac NV's management efficiency
CureVac NV has return on total asset (ROA) of (0.2452) % which means that it has lost $0.2452 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.543) %, meaning that it created substantial loss on money invested by shareholders. CureVac NV's management efficiency ratios could be used to measure how well CureVac NV manages its routine affairs as well as how well it operates its assets and liabilities. As of March 17, 2025, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, CureVac NV's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 0.36, whereas Total Assets are forecasted to decline to about 838.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.11 | 1.90 | |
| Tangible Book Value Per Share | 1.99 | 1.82 | |
| Enterprise Value Over EBITDA | (1.84) | (1.93) | |
| Price Book Value Ratio | 1.87 | 1.77 | |
| Enterprise Value Multiple | (1.84) | (1.93) | |
| Price Fair Value | 1.87 | 1.77 | |
| Enterprise Value | 551 M | 523.5 M |
Evaluating the management effectiveness of CureVac NV allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The CureVac Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 0.1995 | Revenue | Quarterly Revenue Growth 0.905 | Revenue Per Share | Return On Equity |
CureVac NV Corporate Filings
6K | 12th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
CureVac NV Earnings per Share Projection vs Actual
CureVac NV Corporate Management
| Pierre BSc | CFO MD | Profile | |
| Patrick Baumhof | Senior Technology | Profile | |
| AxelSven Malkomes | Chief Officer | Profile | |
| Ronald Plasterk | Senior Innovation | Profile | |
| Igor MSc | Chief Board | Profile | |
| Antony Blanc | Chief MD | Profile | |
| Sarah Fakih | Vice Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.51 | Revenue Per Share | Quarterly Revenue Growth 0.905 | Return On Assets | Return On Equity |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.